PURPOSE: High-dose chemotherapy and autologous stem cell transplant (ASCT) to treat multiple myeloma (MM) and other cancers carries the risk of oral mucositis (OM) with sequelae including impaired nutritional and fluid intake, pain, and infectious complications. As a result of these problems, cancer treatment may have to be interrupted or delayed. In this study, we looked beyond OM's known risk factors of renal function and melphalan dose with a genome-wide association study (GWAS) to evaluate whether genetic variants in conjunction with clinical risk factors influence predisposition for OM. METHODS: Genotyping was performed using Illumina HumanOmni1-Quad v1.0 BeadChip and further assessed for data quality. We tested 892,589 germline single-nucleotide polymorphisms (SNPs) for association with OM among 972 Caucasian patients treated with high-dose melphalan and ASCT in Total Therapy clinical trials (TT2, TT3, TT4) for newly diagnosed MM. Statistical analyses included t tests, stepwise regression modeling, and logistic regression modeling to find baseline clinical factors and genotypes associated with OM. RESULTS: We found that 353 (36.3 %) patients had grades 2-4 OM. Type of treatment protocol, baseline estimated glomerular filtration rate, and melphalan dose along with baseline serum albumin and female gender predicted 43.6 % of grades 2-4 OM cases. Eleven SNPs located in or near matrix metalloproteinase 13, JPH3, DHRS7C, CEP192, CPEB1/LINC00692, FBN2, ALDH1A1, and DMRTA1/FLJ35282 were associated with grades 2-4 OM. The addition of these SNPs increased sensitivity in detecting grades 2-4 OM cases to 52 %. CONCLUSIONS: These SNPs may be important for their roles in inflammatory pathways, epithelial healing, and chemotherapy detoxification.
PURPOSE: High-dose chemotherapy and autologous stem cell transplant (ASCT) to treat multiple myeloma (MM) and other cancers carries the risk of oral mucositis (OM) with sequelae including impaired nutritional and fluid intake, pain, and infectious complications. As a result of these problems, cancer treatment may have to be interrupted or delayed. In this study, we looked beyond OM's known risk factors of renal function and melphalan dose with a genome-wide association study (GWAS) to evaluate whether genetic variants in conjunction with clinical risk factors influence predisposition for OM. METHODS: Genotyping was performed using Illumina HumanOmni1-Quad v1.0 BeadChip and further assessed for data quality. We tested 892,589 germline single-nucleotide polymorphisms (SNPs) for association with OM among 972 Caucasian patients treated with high-dose melphalan and ASCT in Total Therapy clinical trials (TT2, TT3, TT4) for newly diagnosed MM. Statistical analyses included t tests, stepwise regression modeling, and logistic regression modeling to find baseline clinical factors and genotypes associated with OM. RESULTS: We found that 353 (36.3 %) patients had grades 2-4 OM. Type of treatment protocol, baseline estimated glomerular filtration rate, and melphalan dose along with baseline serum albumin and female gender predicted 43.6 % of grades 2-4 OM cases. Eleven SNPs located in or near matrix metalloproteinase 13, JPH3, DHRS7C, CEP192, CPEB1/LINC00692, FBN2, ALDH1A1, and DMRTA1/FLJ35282 were associated with grades 2-4 OM. The addition of these SNPs increased sensitivity in detecting grades 2-4 OM cases to 52 %. CONCLUSIONS: These SNPs may be important for their roles in inflammatory pathways, epithelial healing, and chemotherapy detoxification.
Authors: M C Foncuberta; P J Cagnoni; C H Brandts; R Mandanas; K Fields; H G Derigs; E Reed; S T Sonis; J Fay; F LeVeque; P Pouillart; H Schrezenmeier; R Emmons; E Thiel Journal: J Immunother Date: 2001 Jul-Aug Impact factor: 4.456
Authors: Sergio Giralt; William Bensinger; Mark Goodman; Donald Podoloff; Janet Eary; Richard Wendt; Raymond Alexanian; Donna Weber; David Maloney; Leona Holmberg; Joseph Rajandran; Hazel Breitz; Richard Ghalie; Richard Champlin Journal: Blood Date: 2003-05-01 Impact factor: 22.113
Authors: Shani Ben-Lulu; Yulia Pollak; Jorge Mogilner; Jacob Bejar; Arnold G Coran; Igor Sukhotnik Journal: PLoS One Date: 2012-09-12 Impact factor: 3.240
Authors: Mervi Toriseva; Matti Laato; Olli Carpén; Suvi T Ruohonen; Eriika Savontaus; Masaki Inada; Stephen M Krane; Veli-Matti Kähäri Journal: PLoS One Date: 2012-08-07 Impact factor: 3.240
Authors: Gangwen Han; Li Bian; Fulun Li; Ana Cotrim; Donna Wang; Jianbo Lu; Yu Deng; Gregory Bird; Anastasia Sowers; James B Mitchell; J Silvio Gutkind; Rui Zhao; David Raben; Peter ten Dijke; Yosef Refaeli; Qinghong Zhang; Xiao-Jing Wang Journal: Nat Med Date: 2013-03-10 Impact factor: 53.440
Authors: JiaRui Li; Lin Lu; Yu-Hang Zhang; YaoChen Xu; Min Liu; KaiYan Feng; Lei Chen; XiangYin Kong; Tao Huang; Yu-Dong Cai Journal: Cancer Gene Ther Date: 2019-05-29 Impact factor: 5.987
Authors: Cielito C Reyes-Gibby; Stephanie C Melkonian; Jian Wang; Robert K Yu; Samuel A Shelburne; Charles Lu; Gary Brandon Gunn; Mark S Chambers; Ehab Y Hanna; Sai-Ching J Yeung; Sanjay Shete Journal: PLoS One Date: 2017-07-05 Impact factor: 3.240
Authors: Sebastian Wurster; Oscar E Ruiz; Krystin M Samms; Alexander M Tatara; Nathaniel D Albert; Philip H Kahan; Anh Trinh Nguyen; Antonios G Mikos; Dimitrios P Kontoyiannis; George T Eisenhoffer Journal: Cell Rep Date: 2021-03-23 Impact factor: 9.423